miR-23b-3p Helps Reduce Lung Scarring from Inflammation
Author Information
Author(s): Yue Linlin, Chen Feng, Liu Xin, Wu Chaoyu, Wang Jie, Lai Jiying
Primary Institution: The First Affiliated Hospital of Gannan Medical University
Hypothesis
miR-23b-3p can alleviate pulmonary fibrosis by inhibiting endothelial-to-mesenchymal transition (EndMT) through DPP4 inhibition.
Conclusion
The study found that miR-23b-3p significantly alleviates pulmonary fibrosis by inhibiting EndMT and targeting DPP4.
Supporting Evidence
- miR-23b-3p was significantly down-regulated in LPS-treated HPMECs.
- miR-23b-3p inhibited the expression of DPP4.
- Combined treatment with miR-23b-3p and DPP4 inhibitors showed the strongest effect in alleviating pulmonary fibrosis.
Takeaway
This study shows that a tiny molecule called miR-23b-3p can help fix damaged lungs by stopping certain cells from turning into scar tissue.
Methodology
The study used LPS-induced human pulmonary microvascular endothelial cells and a mouse model to investigate the effects of miR-23b-3p and DPP4 inhibitors on pulmonary fibrosis.
Participant Demographics
25 C57bl/6 specific pathogen-free mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website